WORLDCOM AWARD 2024 in Tokyo Held on Jun 5, 2024
13.6.2024 13:00:00 EEST | Business Wire | Press release
WORLDCOM Public Relations Group held its inaugural "WORLDCOM AWARD 2024 in Tokyo" ceremony in Tokyo, recognizing companies that should be highlighted globally from Japan. The event was organized by AZ WORLDCOM JAPAN Co., Ltd., a member of the WORLDCOM Public Relations Group since 1992. The award ceremony took place on June 5, with representatives from eight distinguished companies receiving accolades from WORLDCOM Public Relations Group's representatives and key executives. Following the ceremony, a reception was held, attended by over 100 participants from 28 countries, celebrating the achievements in grand style.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240609539044/en/
WORLDCOM AWARD 2024 - Ceremony (Photo: Business Wire)
"Each of these companies is truly outstanding and deserves to be showcased to the world. We hope this recognition will further contribute to their continued prosperity." said Stefan Pollack, chairman of the WORLDCOM Public Relations Group and president of the Pollack Group.
“WORLDCOM AWARD 2024 in Tokyo” - Winners
-
Arcuss Japan Inc.
President and CEO: Nobuaki Matsubara
https://www.arcuss-japan.com/ -
HT INTERNATIONAL
President and CEO: Takenori Yamamura
https://www.hti-trade.com/ -
SAKURA Co.,Ltd.
CEO: Kazuyoshi Takahashi
https://www.sakura2012.co.jp/ -
NALU Co.,Ltd.
President and CEO: Tomoko Hori
https://nalu-japan.com/ -
Holon System Co.,Ltd
Chairman: Masahiro Kobayashi
https://www.holon.co.jp/ -
Yokobiki Shutter Co.,Ltd.
CEO: Shinjiro Ichikawa
https://www.yokobiki-shutter.co.jp/ -
Manyou Kensetsu
CEO: Shunichi Sasaki
https://man-you.jp/ -
GATES Inc.
CEO: Yuji Sekino
https://gatestokyo.co.jp/
About the WORLDCOM Public Relations Group
The WORLDCOM Public Relations Group is the world’s leading partnership of independently owned public relations firms, with 143 offices employing some 2,000 staff in 115 cities across six continents. In total, WORLDCOM partners reported combined revenue of US$350+ million last year from 3,034 clients. Established in 1988, the group was formed so that the strongest, most capable independent firms could deliver immediate impact and sustained value through the intelligent use of communications – wherever in the world a client needs support. Partners serve national, international, and multinational clients.
About AZ WORLDCOM Japan Co., Ltd.
AZ WORLDCOM JAPAN Co., Ltd. was founded in 1989, based in Tokyo, Japan, and provides a wide range of PR consulting services for both B2B and B2C clients domestically and internationally. The company has been a member of the WORLDCOM Public Relations Group for over 30 years, contributing significantly to the group's global PR initiatives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609539044/en/
Contacts
AZ WORLDCOM JAPAN Co., Ltd.
TEL: +81-3-5005-0281
E-mail: info@azw.co.jp
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release
Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom